|Bid||77.80 x 800|
|Ask||81.65 x 1000|
|Day's Range||77.20 - 83.79|
|52 Week Range||63.69 - 127.42|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||273.52|
|Earnings Date||Nov 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||121.00|
Subscribe to Yahoo Finance Plus to view Fair Value for NARILearn more
In this article, we discuss the 10 best growth stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Growth Stocks for 2022. The optimism surrounding the global economic recovery has been dented by supply chain concerns and rising inflation. Ratings agency Moody’s estimates that […]
Stock market investing is easier than ever, even if you don't have heaps of cash lying around in your brokerage account. Carefully monitoring organ transplant recipients for initial signs of rejection can save healthcare plan sponsors a bundle. Until CareDx (NASDAQ: CDNA) came along, though, deciding how heavily to compromise a patient's immune system involved a lot of guesswork.
Inari Medical's (NARI) third-quarter results benefit from new product launches and continued U.S. commercial expansion.